Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Papapoulos
S E
SE
Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, NL-2333 ZA Leiden, The Netherlands.
D000284:Administration, Oral; D019386:Alendronate / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006620:Hip Fractures / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control; D000077268:Pamidronate; D010215:Papio; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000517:prevention & control; D013997:Time Factors
D002121:Calcium Channel Blockers; D004164:Diphosphonates; C058651:tiludronic acid; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077268:Pamidronate; D019386:Alendronate